In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Fennec Pharmaceuticals Inc (FENC), with a price target of $18. The company’s shares closed on Friday at $6.19, close to its 52-week low of $5.94.
Selvaraju wrote:
“In our view, PEDMARK is worth roughly $430M to Fennec based on a risk-adjusted net present value (NPV) calculation that employs a 12% discount rate, 85% probability of success and a 26% effective tax rate.”
According to TipRanks.com, Selvaraju ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -14.0% and a 19.8% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.
Currently, the analyst consensus on Fennec Pharmaceuticals Inc is a Moderate Buy with an average price target of $18.
See today’s analyst top recommended stocks >>
The company has a one-year high of $14.99 and a one-year low of $5.94. Currently, Fennec Pharmaceuticals Inc has an average volume of 77.58K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Fennec Pharmaceuticals, Inc. is a small stage biotechnology company, which engages in the development of sodium thiosulfate for the prevention of ototoxicity from cisplatin in pediatric patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.
